Peer-reviewedCC BYFrontiers in pharmacology16 Oct 2026

Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer’s disease: a systematic review and meta-analysis

Shang-Ying Li¹
Jia-Xin Zhang¹
Long-Zhuan Huang¹
Han-Biao Wu¹
Yu-Bing Ye¹
Aiqun Liu²
Jisheng Chen¹
Sha Lai¹

¹Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University , ,
²Department of Neurology, Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University , ,

Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation
Chuo-Yu Lee, Chih-Wei Hsu, Ping-Tao Tseng +9
Alzheimer's Research & Therapy22 Jun 2026Peer-reviewedCC BY-NC-ND 4.0Full textPhysiologyPMC
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.
Lisa Le Scouarnec, Vincent Bouteloup, Leslie Grasset +4
The journal of prevention of Alzheimer's disease14 Oct 2026Peer-reviewedCC BY-NC-NDFull textPhysiologyEurope PMC
DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis.
Bertrand Bourre, Olivier Guerrier, Xavier Ayrignac +7
Journal of neurology22 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Utilisation du lecanemab au stade précoce de la maladie d’Alzheimer au Canada.
Sophie M Weiss, Jennifer A Watt, Vivian Ewa +1
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne4 Oct 2026Peer-reviewedCC BY-NC-NDFull textPhysiologyEurope PMC
Progressive Amyloid‐Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier
Elisabeth Stögmann, Lukas Haider, Joel Leinkauf +10
European journal of neurology1 Oct 2026Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeX

@article{li2026efficacy,
  title = {{Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer’s disease: a systematic review and meta-analysis}},
  author = {Shang-Ying Li and Jia-Xin Zhang and Long-Zhuan Huang and Han-Biao Wu and Yu-Bing Ye and Aiqun Liu and Jisheng Chen and Sha Lai},
  journal = {Frontiers in pharmacology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13655067},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer’s disease: a systematic review and meta-analysis
AU  - Shang-Ying Li
AU  - Jia-Xin Zhang
AU  - Long-Zhuan Huang
AU  - Han-Biao Wu
AU  - Yu-Bing Ye
AU  - Aiqun Liu
AU  - Jisheng Chen
AU  - Sha Lai
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in pharmacology
UR  - https://europepmc.org/article/PMC/PMC13655067
SN  - 1663-9812
ER  -

Related

Cite